As we’ve shared previously, the Alliance for Hippocratic Medicine, et al are challenging the FDA’s various approval of changes to how dangerous chemical abortion pills are regulated. Â
What Does This Mean?
On a positive note, by hearing oral arguments, the ensuing media coverage will help inform women all across America about the changes the FDA has made since 2000.  These changes obfuscate the dangers of chemical abortions because one of the changes the FDA made was to eliminate the requirement to report adverse effects - - except death.  The FDA also changed the limits of administering the drug by gestation period from 7 weeks to 10 weeks AND eliminated the need for required doctor’s visits prior to and after administering the pills.  All of these changes have put women’s health and safety at risk and they likely don’t know it.
Recently released CDC data from 2021 shows that chemical abortions are now up to 56% of all abortions. Â In 2023, we believe that number is even higher. Â That means the outcome of this case could possibly immediately save tens of thousands of lives. Â
History
The plaintiffs argue that the FDA unlawfully fast-tracked the approval and never studied the safety of the drugs under the labeled condition for use. The FDA characterized pregnancy as an “illness” and never studied the safety of the drugs for use in abortions.  Since 2000, the FDA has:
According to the complaint, FDA’s approval of mifepristone and misoprostol’s use for abortions should be reversed,
“To date, the FDA’s review, approval, and deregulation of chemical abortion drugs has spanned three decades, correlated with four U.S. presidential elections, and encompassed six discrete agency actions. Plaintiffs challenge these six FDA actions and ask that the Court hold them unlawful, set them aside, and vacate them.” Case no. 2:22-cv-00223-Z, Complaint, p. 2
Georgia’s Attorney General Chris Carr joined with 21 other state Attorneys General in filing an amicus brief supporting the Plaintiffs. Â
Additionally, eight (8) members of Georgia’s Congressional delegation also signed on to an amicus brief supporting the Plaintiffs.